Biotech M&A? Novartis chief Jimenez says he’s sticking to the under-$1B aisle for now
Novartis never did say just what kind of deal it put together in buying Ziarco late last year. But Bloomberg had already reported that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
